Sign Up
Stories
Decongestants Found to be Useless, Eye Drop Products Contaminated, and Teva Settles Over Yupelri Inhalation Drug
Share
Amgen and Pfizer Complete Acquisitions b...
Biotech Acquisitions & Layoffs
Decongestants and Eye Drops: Ineffective...
Amgen to Lay Off Horizon Employees After...
Avenova-branded Products in EU Market
Axsome's FDA Setback Sparks Investigatio...
Overview
API
Decongestants containing phenylephrine are found to be ineffective, yet they are still sold on pharmacy shelves. The FDA has issued warnings about contaminated eye drop products. Teva Pharmaceutical Industries settles with Theravance Biopharma and Mylan over their inhalation drug Yupelri.
Ask a question
How can the FDA ensure the effectiveness of over-the-counter products?
What impact does the settlement between Teva and Theravance Biopharma have on the pharmaceutical industry?
What measures can be taken to prevent contamination in eye drop products?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jun 2023
Jul 2023
Aug 2023
Sep 2023
Oct 2023
Coverage